as of 11-20-2026 1:02pm EST
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2017 |
| Target Price: | $10.67 | AVG Volume (30 days): | 58.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -17.41 | EPS Growth: | -338.60 |
| 52 Week Low/High: | $3.02 - $4.97 | Next Earning Date: | 11-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.22 | Index: | N/A |
| Free Cash Flow: | -6557208.0 | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Nov 12, 2026
2 ea031195201ex99-1.htm
Exhibit 99.1
Azora Therapeutics Reports 2026 Third Quarter Financial Results
and Provides Business Update
Azora Therapeutics commenced trading on Nasdaq as “AZR”
New executive team and Board of Directors appointed
AT177 IND submission and Phase 1a initiation on track for the first half of 2027
Los Angeles, CA, November 12, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR) (“Azora” or the “Company”), a biopharmaceutical company developing locally acting treatments for serious immune-mediated and inflammatory diseases, today provided a business update and reported its financial results for the third quarter ended September 30, 2026.
During the quarter, Azora continued to advance AT177 through IND-enabling studies and expanded its scientific and operating team. AT177 is a proprietary, oral, colon-targeted aryl-hydrocarbon receptor (AhR) agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure.
“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis,” said Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer. “We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”
Corporate Highlights
●New name and Nasdaq ticker. Effective October 29, 2026, the Company changed its name from Adial Pharmaceuticals, Inc. to Azora Therapeutics, Inc., and its common stock began trading on The Nasdaq Capital Market under the symbol “AZR.”
●Stockholder approvals. On October 28, 2026, the Company’s stockholders approved all remaining transaction matters, including the conversion of the Series A preferred stock and the exercise of the pre-funded and milestone warrants. On November 2, 2026, 9,924.260 shares of Series A preferred stock converted into 9,924,260 shares of common stock. The remaining 3,006.341 shares of Series A preferred stock remain outstanding and convertible into 3,006,341 shares of common stock, subject to beneficial ownership limitations.
New executive team
The following were appointed to executive roles at Azora effective October 28, 2026:
●Matt Davidson, Ph.D., Azora co-founder, was appointed President and Chief Executive Officer. He previously founded Verrica Pharmaceuticals and led development of the first FDA-approved treatment for molluscum contagiosum.
●Celia Economides was appointed Chief Financial Officer based on her more than 20 years of biopharma finance leadership across public and private companies.
●Julie Saiki, Ph.D., Azora co-founder, was appointed Chief Strategy Officer. Her research at Stanford helped establish AhR activation as a potential therapeutic approach for ulcerative colitis and provided the scientific foundation for
●David Rubenstein, M.D., Ph.D., joined as Chief Scientist. As Chief Scientific Officer of Dermavant Sciences, he led tapinarof (VTAMA® cream 1%), the first FDA-approved AhR agonist, through development and approval.
New Board of Directors
On November 3, 2026, the Board appointed three independent directors, joining Dr. Davidson, who serves as Chair, and Wendy Young, Ph.D., former Senior Vice President of Small Molecule Drug Discovery at Genentech:
●Aida Habtezion, M.D., former Chief Medical Officer of Pfizer and former Stanford gastroenterologist whose research included the role of AhR in intestinal immunity.
●Paul Hastings, Chief Executive Officer of Nkarta and former Chair of the Biotechnology Innovation Organization (BIO).
●Thomas Soloway, Chief Executive Officer of T-knife Therapeutics and former Chief Financial Officer of Audentes Therapeutics and Ascendis Pharma, chairs the Audit Committee.
Milestone financing
On September 16 and September 30, 2026, the Company amended its securities purchase agreement and note exchange agreements to remove a provision that reduced investors’ milestone warrant purchase rights by the percentage of their initial closing pre-funded warrants exercised. Up to approximately $32.4 million in gross proceeds could be received if investors elect to purchase the milestone warrants.
AT177 Program Update and Milestones
●IND-enabling studies continued, building on completed GLP toxicology studies and pre-IND feedback from the FDA.
●GMP manufacturing initiated to support clinical development of AT177.
●First half of 2027: Planned IND submission and init
See how AZR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "AZR Azora Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.